Company Email Format Management

Apellis Pharmaceuticals

Biotechnology Research Ch 783 employees

Employees: 783
Contacts: 4
Emails: 4
Phones: 1

apellis.com LinkedIn Crunchbase

Apellis Pharmaceuticals Overview

Headquarters: Ch
Phone Number: Available in AeroLeads
Website: apellis.com
Industry: Biotechnology Research
Employees: 783
Founded: 2008
Funding: 275.0M
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Targeted C3 Therapies Complement System Hematology Ophthalmology Nephrology Paroxysmal Nocturnal Hemoglobinuria (PNH) Geographic Atrophy (GA) C3 Glomerulopathy (C3G) Cold Agglutinin Disease (CAD) Gene Therapy Neurology Amyotrophic Lateral Sclerosis (ALS)

About Apellis Pharmaceuticals

At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8

Apellis Pharmaceuticals Contact Details

People in AeroLeads: 4
With contact data: 4
Email contacts: 4; 100.0% coverage
Phone contacts: 1; 25.0% coverage

Apellis Pharmaceuticals Org Chart

Sample employees and titles

Name	Title	Location	Contact
Natalya Gromyko	Biopharma New Product Planning Leader	Greater Boston, United States	Email Phone
Kira Tsivkin		Newton Centre, Massachusetts, United States	Email
Lisa Paul-Stark	Patient Focused Rare Disease Medical	Greater Philadelphia, United States	Email
Renaud Desgraz, Phd		Basel, Switzerland	Email